Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerKoji Haratani, Kazuhiko Nakagawa, Hidetoshi Hayashi et al.|JAMA Oncology|2017Cited by 1k
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 393
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Hidetoshi Hayashi et al.|Annals of Oncology|2017Cited by 294
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Toshio Kubo et al.|Journal of Clinical Oncology|2023Cited by 293
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung CancerKohsuke Isomoto, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2020Cited by 244